medigraphic.com

2003, Number 1

<< Back

Bioquimia 2003; 28 (1)

Monitoring of cyclosporine A in renal trasplant: Its impact over the nephrotoxicity effect

Lizette Bonet-Roselló, Esther González-Porto, Jorge Suardíaz-Pereras,Jorge Meleán-Consuegra, Yolanda Trujillo-Alvarez

Language: Spanish
References: 21
Page: 13-16
PDF size: 109.23 Kb.


ABSTRACT

In 109 patients with renal transplant, the cyclosporine A levels in whole blood were determined prior to the administration of the first dose of the day using the high performance liquid chromatography with extraction in solid phase, as well as the serum creatinine and urea concentrations and the index urine/ serum creatinine by autoanalyzer methodology. The patients with cyclosporine A levels higher than 250 ng/mL had nephrotoxicity symptoms. In this group, we found a significant positive correlation between cyclosporine A and serum creatinine levels, and a significant negative correlation between cyclosporine A levels and the index urine/ serum creatinine. The previous, in addition to cyclosporine A levels out of therapeutic range in the 36.7% of the studied patients, showed the importance of the periodical monitorig of cyclosporine A levels in patients who are receiving it.


REFERENCES

  1. De Carlis L, Belli LS, Rondinara GF, Alberti A, Sansalone CV, Colella G, etal. Early Steroid Withdrawal in Liver Transplant Patients: Final Report ofa Prospective Randomized Trial. Transplant Proc 1997; 29: 539-42.

  2. Hausen B, Boeke K, Berry GJ, Segarra I, Benet L, Christian U, et al.Coadministration of neoral and the novel rapamycin analog, SDZ RAD,to rat lung allograft recipients. Transplant 1999; 67 (7): 956-62.

  3. Ligtenberg G, Hené R, Blankestijn P, Koomans A. Cardiovascular riskfactors in renal transplant patients: Cyclosporin A versus tracolimus.J Am Soc Nephrol 2001; 12: 368-73.

  4. Deray G, Benhmida M, Le-Hoang P, Maksud P, Aupetit B, Baumelou A,et al. Renal function and blood pressure in patients receiving long-term, low dose cyclosporine therapy for idiopathic autoimmune uveitis.Ann Intern Med 1992; 177 (7): 578-83.

  5. Young EW, Ellis ON, Messana JM, Johnson KJ, Leichtman AB, MihatschMJ, et al. A prospective study of renal structure and function inpsoriasis patients treated with cyclosporin. Kidney Int 1994; 46 (4):1216-22.

  6. David-Neto E, Carvalhinho FB, Furusawa EA, Schwartzman BS, CavalcanteJS, Yagyu EM, et al. Impact of Cyclosporin A pharmacokinetics on thepresence of side effects in pediatric renal transplantation. J Am SocNephrol 2000; 11: 343-49.

  7. Quesniaux V. Pharmacology of Cyclosporine (Sandimmune). IIIImmunochemistry and Monitoring. Pharmacolog Reviews 1989; 41(3): 249-58.

  8. McKay, Milford y Sayech. Clinical aspects of renal transplantation. InThe Kidney. Fiftth Edition. Edited by Barry M. Brenner. SAUNDER, EUA,1996: 2625.

  9. González E, Bonet L, Suardíaz J, Meleán J, Valdés R. Determinación dela Ciclosporina A en sangre total mediante la Cromatografía Líquida deAlta Resolución con extracción en fase sólida. Bioquimia 1997; 22(2): 689-92.

  10. Goodman LS, Goodman Gilman A, Rall TW. Las bases farmacológicas dela terapéutica. 8va ed. México, Buenos Aires: Médica Panamericana;1993: 1226.

  11. Isoniemi H, Krogerus L, Von Willebrand E, Taskinen E, Gronhagen-Riska C, Ahonen J, et al. Renal allograft immunosuppression. Tripledrug therapy versus immunosuppressive double drug combinations:histopathological finding in renal allograft. Transplant Int 1991; 4:151-6.

  12. Venkateswara K, Crosson JT, Kjellstrand CM. Chronic IrreversibleNephrotoxicity from Cyclosporin A. Nephron 1985; 41: 75-7.

  13. Thiel G, Bock A, Spondlin M, Brunner FP, Mihatsch M, Rufli T, et al.Long term beneficts and risks of cyclosporine A (Sandimmun)-ananalysis at 10 years. Transplant Proc 1994; 26(5): 2493-8.

  14. Zachariae H, Hansen HE, Kragballe K, Olsen S. Morphologic renalchanges during cyclosporine treatment of psoriasis. Studies onpretreatment and post-treatment. Kidney biopsy specimens. J Am AcadDermatol 1992; 26: 415-9.

  15. Zaltzman JS, Pei Y, Maurer J, Patterson A, Cattran DC. Cyclosporinenephrotoxicity in lung transplant recipients. Transplant 1992; 54(5): 875-8.

  16. Ryffel B, Hiestand P, Foxwell B, Donatsch P, Boelsterli HJ, Maurer G,et al. Nephrotoxic and immunosuppressive potentials of cyclosporinemetabolites in rats. Transplant Proc 1986; 18(5): 41-5.

  17. Moyer TP, Lawson GM. Therapeutic Drug Monitoring. In ClinicalLaboratory Medicine. Edited by Kenneth D. McClatchey. Williams andWilkins, USA, 1994: 417.

  18. Nankivell BJ, Hibbins M, Chapman JR. Diagnostic utility of wholeblood cyclosporine measurements in renal transplantation using tripletherapy. Transplant 1994; 58: 989-96.

  19. Oellerich M, Armstrong VW, Kahan B, Shaw L, Holt DW, Yatscoff R, et al.Lake Louise consensus conference on cyclosporine monitoring inorgan transplantation: Report of the consensus panel. Ther DrugMonit 1995; 17: 642-54.

  20. Lindholm A, Kahan BD. Influence of Cyclosporine pharmacokinetics,trough concentrations, and AUC monitoring on outcome after kidneytranplantattion. Clin Pharmacol Ther 1993; 54: 205-18.

  21. Mahalati K, Belitsky P, West K, Kiberd B, Fraser A, Sketris I, et al.Approaching the therapeutic window for Cyclosporine in KidneyTransplantation: A prospective study. J Am Soc Nephrol 2001; 12: 828-33.




2020     |     www.medigraphic.com